FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792383110> ?p ?o ?g. }

• W2792383110 endingPage "1858" @default.
• W2792383110 startingPage "1845" @default.
• W2792383110 abstract "Abstract Small-molecule inhibitors of the mTORC2 kinase (torkinibs) have shown efficacy in early clinical trials. However, the torkinibs under study also inhibit the other mTOR-containing complex mTORC1. While mTORC1/mTORC2 combined inhibition may be beneficial in cancer cells, recent reports describe compensatory cell survival upon mTORC1 inhibition due to loss of negative feedback on PI3K, increased autophagy, and increased macropinocytosis. Genetic models suggest that selective mTORC2 inhibition would be effective in breast cancers, but the lack of selective small-molecule inhibitors of mTORC2 have precluded testing of this hypothesis to date. Here we report the engineering of a nanoparticle-based RNAi therapeutic that can effectively silence the mTORC2 obligate cofactor Rictor. Nanoparticle-based Rictor ablation in HER2-amplified breast tumors was achieved following intratumoral and intravenous delivery, decreasing Akt phosphorylation and increasing tumor cell killing. Selective mTORC2 inhibition in vivo, combined with the HER2 inhibitor lapatinib, decreased the growth of HER2-amplified breast cancers to a greater extent than either agent alone, suggesting that mTORC2 promotes lapatinib resistance, but is overcome by mTORC2 inhibition. Importantly, selective mTORC2 inhibition was effective in a triple-negative breast cancer (TNBC) model, decreasing Akt phosphorylation and tumor growth, consistent with our findings that RICTOR mRNA correlates with worse outcome in patients with basal-like TNBC. Together, our results offer preclinical validation of a novel RNAi delivery platform for therapeutic gene ablation in breast cancer, and they show that mTORC2-selective targeting is feasible and efficacious in this disease setting. Significance: This study describes a nanomedicine to effectively inhibit the growth regulatory kinase mTORC2 in a preclinical model of breast cancer, targeting an important pathogenic enzyme in that setting that has been undruggable to date. Cancer Res; 78(7); 1845–58. ©2018 AACR." @default.
• W2792383110 created "2018-03-29" @default.
• W2792383110 creator A5004009810 @default.
• W2792383110 creator A5004288107 @default.
• W2792383110 creator A5012443866 @default.
• W2792383110 creator A5016849692 @default.
• W2792383110 creator A5030367169 @default.
• W2792383110 creator A5033568550 @default.
• W2792383110 creator A5037252693 @default.
• W2792383110 creator A5037945408 @default.
• W2792383110 creator A5041028923 @default.
• W2792383110 creator A5041525182 @default.
• W2792383110 creator A5044622075 @default.
• W2792383110 creator A5054762208 @default.
• W2792383110 creator A5067192228 @default.
• W2792383110 creator A5075794128 @default.
• W2792383110 creator A5090276311 @default.
• W2792383110 date "2018-04-01" @default.
• W2792383110 modified "2023-10-18" @default.
• W2792383110 title "Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival" @default.
• W2792383110 cites W1523693806 @default.
• W2792383110 cites W1574172480 @default.
• W2792383110 cites W1829589101 @default.
• W2792383110 cites W1844274376 @default.
• W2792383110 cites W1963533510 @default.
• W2792383110 cites W1963727587 @default.
• W2792383110 cites W1977267072 @default.
• W2792383110 cites W1978194521 @default.
• W2792383110 cites W1983698019 @default.
• W2792383110 cites W1992170852 @default.
• W2792383110 cites W2000269004 @default.
• W2792383110 cites W2000731858 @default.
• W2792383110 cites W2007347651 @default.
• W2792383110 cites W2014001512 @default.
• W2792383110 cites W2015235010 @default.
• W2792383110 cites W2025935112 @default.
• W2792383110 cites W2026842712 @default.
• W2792383110 cites W2031469256 @default.
• W2792383110 cites W2056028296 @default.
• W2792383110 cites W2058700971 @default.
• W2792383110 cites W2059259875 @default.
• W2792383110 cites W2060433961 @default.
• W2792383110 cites W2061673659 @default.
• W2792383110 cites W2063432148 @default.
• W2792383110 cites W2065603844 @default.
• W2792383110 cites W2067019627 @default.
• W2792383110 cites W2067302150 @default.
• W2792383110 cites W2068942685 @default.
• W2792383110 cites W2072589601 @default.
• W2792383110 cites W2080718344 @default.
• W2792383110 cites W2092105616 @default.
• W2792383110 cites W2092626295 @default.
• W2792383110 cites W2095567148 @default.
• W2792383110 cites W2095949683 @default.
• W2792383110 cites W2096691828 @default.
• W2792383110 cites W2110083155 @default.
• W2792383110 cites W2118073504 @default.
• W2792383110 cites W2118978588 @default.
• W2792383110 cites W2126783165 @default.
• W2792383110 cites W2127063807 @default.
• W2792383110 cites W2134539328 @default.
• W2792383110 cites W2134572635 @default.
• W2792383110 cites W2137518600 @default.
• W2792383110 cites W2139712038 @default.
• W2792383110 cites W2153607816 @default.
• W2792383110 cites W2155239981 @default.
• W2792383110 cites W2157983986 @default.
• W2792383110 cites W2161428561 @default.
• W2792383110 cites W2164087025 @default.
• W2792383110 cites W2167215180 @default.
• W2792383110 cites W2172712090 @default.
• W2792383110 cites W2314993208 @default.
• W2792383110 cites W2342715069 @default.
• W2792383110 cites W2353363793 @default.
• W2792383110 cites W2397317955 @default.
• W2792383110 cites W2412326609 @default.
• W2792383110 cites W2535462468 @default.
• W2792383110 cites W2599900557 @default.
• W2792383110 cites W2730375672 @default.
• W2792383110 cites W4238567307 @default.
• W2792383110 cites W837244897 @default.
• W2792383110 doi "https://doi.org/10.1158/0008-5472.can-17-2388" @default.
• W2792383110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5882532" @default.
• W2792383110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29358172" @default.
• W2792383110 hasPublicationYear "2018" @default.
• W2792383110 type Work @default.
• W2792383110 sameAs 2792383110 @default.
• W2792383110 citedByCount "45" @default.
• W2792383110 countsByYear W27923831102018 @default.
• W2792383110 countsByYear W27923831102019 @default.
• W2792383110 countsByYear W27923831102020 @default.
• W2792383110 countsByYear W27923831102021 @default.
• W2792383110 countsByYear W27923831102022 @default.
• W2792383110 countsByYear W27923831102023 @default.
• W2792383110 crossrefType "journal-article" @default.
• W2792383110 hasAuthorship W2792383110A5004009810 @default.
• W2792383110 hasAuthorship W2792383110A5004288107 @default.
• W2792383110 hasAuthorship W2792383110A5012443866 @default.

• next